指南与共识贫血与红细胞疾病血栓与止血

美国血液学会2019年镰状细胞病指南:心肺与肾脏疾病

American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.
指南 / 共识 · Blood Adv · 2019-01-01

美国血液学会(ASH)针对镰状细胞病(SCD)心肺与肾脏并发症的筛查、诊断和管理制定了循证指南。多学科小组基于截至2017年9月的系统综述,采用GRADE方法形成10条推荐,并包含成人SCD合并静脉血栓栓塞的抗凝疗程推荐。多数推荐为条件性,因缺乏直接高质量证据。

要点

  • 指南涵盖SCD心肺与肾脏并发症的筛查、诊断和管理。
  • 共形成10条推荐,采用GRADE方法评估证据。
  • 多数推荐为条件性,因缺乏直接高质量证据。

核心结论

  • ASH发布了针对SCD心肺与肾脏并发症管理的循证指南,共10条推荐。
  • 多数推荐为条件性,因缺乏直接高质量证据。

研究设计与样本

  • ASH组建多学科指南小组,包括2名患者代表,由Mayo证据-based实践研究项目支持。
  • 系统证据回顾截至2017年9月,采用GRADE方法评估证据并形成推荐。

主要发现

  • 小组就SCD心肺与肾脏并发症的筛查、诊断和管理达成10条推荐。
  • 还制定了成人SCD合并静脉血栓栓塞的抗凝疗程推荐。

临床怎么用

  • 指南旨在支持患者、临床医生和其他医疗专业人员对SCD心肺与肾脏并发症进行决策。

局限性

  • 多数推荐为条件性,因缺乏直接高质量证据。
  • 需要前瞻性研究了解心肺与肾脏疾病的自然史及其与患者重要结局的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. METHODS: ASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed. CONCLUSIONS: Most recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Liem RI, Lanzkron S, D Coates T, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019. PMID: 31794601. doi:10.1182/bloodadvances.2019000916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。